We are live on ! Find out more
OLMA icon

Olema Pharmaceuticals

133 hedge funds and large institutions have $248M invested in Olema Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 43 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 43

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

15% less funds holding

Funds holding: 156133 (-23)

27.95% less ownership

Funds ownership: 124.4%96.44% (-28%)

40% less capital invested

Capital invested by funds: $415M → $248M (-$167M)

49% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 47

79% less call options, than puts

Call options by funds: $27K | Put options by funds: $128K

Holders
133
Holders Change
-23
Holders Change %
-14.74%
% of All Funds
1.78%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
48
Reduced
43
Closed
47
Calls
$27K
Puts
$128K
Net Calls
-$101K
Net Calls Change
-$1.83M
Name Holding Trade Value Shares
Change
Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$25.7M -$3.15M -626,260 -8%
PBA
2
Paradigm Biocapital Advisors
New York
$25.3M -$2.84M -563,798 -8%
BI
3
BVF Inc
California
$19.9M -$2.11M -420,000 -7%
BlackRock
4
BlackRock
New York
$14.4M +$164K +32,510 +0.9%
DTC
5
Deep Track Capital
Connecticut
$12.9M
LGM
6
Logos Global Management
California
$12.1M
Franklin Resources
7
Franklin Resources
California
$11.3M +$13.8M +2,738,263 +1,000%
MB
8
MPM BioImpact
Massachusetts
$11M +$90K +17,896 +0.6%
Vanguard Group
9
Vanguard Group
Pennsylvania
$10.8M +$939K +186,604 +7%
LMC
10
Lightspeed Management Company
California
$7.26M
Pictet Asset Management
11
Pictet Asset Management
Switzerland
$7.07M -$21.8K -4,341 -0.2%
Citadel Advisors
12
Citadel Advisors
Florida
$7.04M +$953K +189,421 +11%
VC
13
Vivo Capital
California
$5.66M
WP
14
Woodline Partners
California
$5.56M +$606K +120,428 +9%
Wellington Management Group
15
Wellington Management Group
Massachusetts
$5.54M -$261K -51,805 -3%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$5.42M -$11.2M -2,229,136 -61%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$4.96M -$68.5K -13,613 -1%
UBS Group
18
UBS Group
Switzerland
$4.33M +$2.97M +590,641 +105%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$4.07M +$789K +156,964 +17%
Millennium Management
20
Millennium Management
New York
$3.68M -$1.87K -371 -0%
Bank of America
21
Bank of America
North Carolina
$3.42M +$217K +43,209 +5%
State Street
22
State Street
Massachusetts
$3.25M -$4.99M -991,971 -53%
CS
23
Candriam SCA
Luxembourg
$3.2M -$3.53M -701,045 -45%
PC
24
Pier Capital
Connecticut
$3.08M +$2.74M +545,589 +200%
Goldman Sachs
25
Goldman Sachs
New York
$2.79M +$1.8M +358,412 +94%

OLMA Hedge Fund Activity: Q1 2025 in Review

133 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q1 2025, worth a combined $248M — down 40% from $415M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of OLMA and 24 opened new positions — a net loss of 23 holders — while 43 trimmed existing stakes and 48 added.

The largest buyer was Franklin Resources, adding an estimated $13.8M. The largest seller was Point72 Asset Management, cutting an estimated $11.2M.

  • 133 institutional investors held Olema Pharmaceuticals (OLMA) as of Q1 2025, down from 156 in Q4 2024.
  • Funds reported $248M of Olema Pharmaceuticals stock for Q1 2025, down 40% quarter-over-quarter.
  • 24 funds opened new Olema Pharmaceuticals positions in Q1 2025 and 47 closed out, a net change of -23 holders.
  • The largest Olema Pharmaceuticals buyer in Q1 2025 was Franklin Resources, an estimated $13.8M added.
  • The largest Olema Pharmaceuticals seller in Q1 2025 was Point72 Asset Management, an estimated $11.2M sold.

Based on aggregated 13F filings for Q1 2025.